Spleen Tyrosine Kinase Inhibition Has Promise in High-Risk Precursor B-Cell ALL


Get Permission

In a study reported in Science Translational Medicine, Perova and colleagues found that pre–B-cell receptor–independent spleen tyrosine kinase signaling was necessary for leukemic B-cell survival and proliferation in a mouse model. Investigation of samples from pediatric and adult B-cell acute lymphoblastic leukemia (ALL) showed that spleen tyrosine kinase and downstream targets were phosphorylated independently of pre–B-cell receptor expression or genetic subtype.

Studies with two small-molecule spleen tyrosine kinase inhibitors showed reduced growth in vitro of B-cell ALL subtypes, including high-risk subtypes. Treatment of immunodeficient mice with one of the inhibitors reduced disease burden in high-risk B-cell ALL xenografts and decreased dissemination of leukemia into the spleen, liver, kidney, and central nervous system.

The investigators concluded, “[Spleen tyrosine kinase] activation sustains the growth of multiple [high-risk] B-ALL subtypes, suggesting that [spleen tyrosine kinase] inhibitors may improve outcomes for [high-risk] and relapsed B-ALL.” ■

Perova T, et al: Sci Transl Med 6:236ra62, 2014


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.